Philogen S.p.A.

Milan Stock Exchange:PHIL.MI

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

Italy

Market Cap

USD 1.24 B

Share Price

USD 30.92

Avg Daily Volume

9,841

Change (1 day)

-0.24%

Change (1 year)

43.92%

Change (YTD)

52.36%

Philogen S.p.A. Share Price Year-To-Date (YTD) return on June 19, 2025: 52.36%

Philogen S.p.A. Share Price Year-To-Date (YTD) return is 52.36% on June 19, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Philogen S.p.A. 52-week low Share Price is USD 31.73 on June 19, 2025, which is 2.63% above the current Share Price.
Philogen S.p.A. 52-week low Share Price is USD 18.12 on June 19, 2025, which is -41.38% below the current Share Price.
Philogen S.p.A. average Share Price for the last 52 weeks is USD 22.10.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

Milan Stock Exchange: PHIL.MI

Philogen S.p.A.

CEO	Prof. Dario Neri Ph.D.
IPO Date	March 3, 2021
Location	Italy
Headquarters	Via Bellaria, 35
Employees	174
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.